首次年度盈利！创新药龙头正式步入收获期？港股通创新药ETF（520880）宽幅溢价，买盘尤为活跃！

Core Viewpoint - BeiGene, a leading innovative drug company, reported a significant performance improvement for the fiscal year 2025, achieving a revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, marking its first annual profit [1][7]. Financial Performance - Total revenue for the reporting period was 38.205 billion yuan, compared to 27.214 billion yuan in the same period last year, reflecting a growth of 40.4% [2][8]. - Product revenue reached 37.770 billion yuan, up 39.9% from 26.994 billion yuan year-on-year [2][8]. - Operating profit was 2.562 billion yuan, a significant recovery from a loss of 4.162 billion yuan in the previous year [2][8]. - The total profit was 2.558 billion yuan, also recovering from a loss of 4.163 billion yuan [2][8]. - The net profit attributable to the parent company was 1.422 billion yuan, compared to a loss of 4.978 billion yuan in the previous year [2][8]. - The net profit excluding non-recurring gains and losses was 1.381 billion yuan, recovering from a loss of 5.379 billion yuan [2][8]. Product Performance - The growth in revenue was primarily driven by the strong sales of core products, with global sales of Baiyueze reaching 28.067 billion yuan, a year-on-year increase of 48.8% [1][7]. - Several candidate drugs are entering critical clinical stages, with Baiyueda approved for market in China and BGB-B2033 receiving FDA fast track designation [1][7]. Market Reaction - Despite the positive financial results, BeiGene's stock price did not perform well, dropping 9.16% on the previous day and over 1% in early trading the following day [2][8]. - Market concerns may stem from the quality of earnings, slowing revenue growth, and pressure on expenses [2][8]. Industry Context - The innovative drug sector is experiencing a transition from "scale accumulation" to "value release," with a focus on commercial gains from pipeline expectations [3][9]. - The innovative drug sector has seen a two-quarter adjustment, but long-term prospects for quality stocks appear favorable, suggesting increased attention to investment opportunities [3][9].